Safety Study of Repeat Doses of SUSTOL in Adults

Status Active, not recruiting

Clinical Trial Summary

This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05434663
Study type	Interventional
Source	Heron Therapeutics
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 6, 2022
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01594749` - Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)	Phase 3
Not yet recruiting	`NCT04912271` - Granisetron Transdermal Patch for Prophylaxis of Delayed CINV	Phase 3
Recruiting	`NCT04472143` - Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents	Phase 2
Completed	`NCT00619359` - Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)	Phase 3
Completed	`NCT03204279` - PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting	Phase 2
Completed	`NCT00952341` - Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)	Phase 3
Completed	`NCT01111851` - Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)	Phase 1